A Phase I Evaluation of the Effect of Ketoconazole on the Pharmacokinetics and Safety of Dihydroergotamine Mesylate (DHE) Delivered by Oral Inhalation (MAP0004) in Healthy Volunteers Compared to DHE Delivered Intravenously (DHE 45).

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 29 Jan 2014

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dihydroergotamine mesilate (Primary) ; Dihydroergotamine mesilate (Primary) ; Ketoconazole
Indications Migraine; Mycoses
Focus Pharmacokinetics
Sponsors Allergan

Most Recent Events

15 Dec 2011 Results published in the Cephalalgia.
07 Nov 2011 Simbec Research added as a trial associate as reported by ClinicalTrials.gov.
07 Nov 2011 Trial location added as reported by ClinicalTrials.gov.

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight